IL-13Rα2介导的毒素融合蛋白在肿瘤治疗中的应用

近年来IL-13受体IL-13Rα2的研究已经成为一个新兴热点，IL-13Rα2在许多肿瘤细胞细胞表面存在特异性高表达，而在正常组织中不表达或表达量很低，通过IL-13Rα2介导的毒素融合蛋白靶向治疗肿瘤也已成为肿瘤诊断和免疫治疗研究中的重要方面。随着对IL-13Rα-结构和功能及其与肿瘤关系研究的不断深入，将为肿瘤的靶向治疗提供新的思路，为肿瘤的临床治疗提供新的理论依据。对IL-13Rα2在不同肿瘤中的表达及IL-13和不同毒素融合得到的毒素融合蛋白在细胞和动物体内等不同水平上对肿瘤治疗的作用做出了相应概括，并对通过IL-13Rα2介导的毒素融合蛋白治疗肿瘤机理的研究以及融合蛋白方法改进及其它相关治疗方法等方面作出综述。

Application of IL-13Rα2-directed Toxin Fusion Protein in Tumor Therapy

The research of interleukin13 receptor α2 (IL-13Rα2) chain is a rising pop these years. Previous studies have shown that many human tumors overexpress IL-13Rα2 chain, while normal cells do not express this receptor or express very low level. This difference of express level is significant to diagnose and cure tumors by the IL-13Rα2-directed toxin fusion protein. During the past decade, the structure and the function of IL-13Rα2 together with the relationship between this receptor and tumors has been further developed. Therefore new therapies and theories can be proposed as the clinical tumor treatments. In this case,the expression in various tumor cell lines was not only focused on but also on the IL-13 and toxin fusion protein killing effect in both the cell level and the in vivo level. Besides,an overview of the mechanism in the treatment of IL-13Rα2-directed toxin fusion protein together with the improved methods for fusion protein purification and other relative tumor therapy was given. In conclusion,the current status and progress of IL-13Rα2 as well as IL-13Rα2-directed toxin fusion protein in tumor therapy were represented.